In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors - Wikidata - awgldk - TriplyDB

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

http://www.wikidata.org/entity/Q29620622

about

Bile pigments as HIV-1 protease inhibitors and their effects on HIV-1 viral maturation and infectivity in vitro Guidelines for antiretroviral therapy for HIV infection. Canadian HIV Trials Network Antiretroviral Working Group.Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors Engineering human immunodeficiency virus 1 protease heterodimers as macromolecular inhibitors of viral maturation Virus maturation as a new HIV-1 therapeutic target Anti-AIDS agents 69. Moronic acid and other triterpene derivatives as novel potent anti-HIV agents Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)Assessment of FIV-C infection of cats as a function of treatment with the protease inhibitor, TL-3 Selection of functional variants of the NS3-NS4A protease of hepatitis C virus by using chimeric sindbis viruses Chimeric Sindbis viruses dependent on the NS3 protease of hepatitis C virus Structural and kinetic analysis of drug resistant mutants of HIV-1 protease Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody Structural studies of FIV and HIV-1 proteases complexed with an efficient inhibitor of FIV protease Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease The structural bases of antibiotic resistance in the clinically derived mutant beta-lactamases TEM-30, TEM-32, and TEM-34 Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy Design and Synthesis of HIV-1 Protease Inhibitors Incorporating Oxazolidinones as P2/P2‘ Ligands in Pseudosymmetric Dipeptide Isosteres Computational design and experimental study of tighter binding peptides to an inactivated mutant of HIV-1 protease Ninety-Nine Is Not Enough: Molecular Characterization of Inhibitor-Resistant Human Immunodeficiency Virus Type 1 Protease Mutants with Insertions in the Flap Region HIV-1 Protease Inhibitors from Inverse Design in the Substrate Envelope Exhibit Subnanomolar Binding to Drug-Resistant Variants Evaluating the Substrate-Envelope Hypothesis: Structural Analysis of Novel HIV-1 Protease Inhibitors Designed To Be Robust against Drug Resistance Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters Structure of the HIV-1 Frameshift Site RNA Bound to a Small Molecule Inhibitor of Viral Replication Nine crystal structures determine the substrate envelope of the MDR HIV-1 protease Structural and Thermodynamic Basis of Amprenavir/Darunavir and Atazanavir Resistance in HIV-1 Protease with Mutations at Residue 50 Extreme Multidrug Resistant HIV-1 Protease with 20 Mutations Is Resistant to Novel Protease Inhibitors with P1′-Pyrrolidinone or P2-Tris-tetrahydrofuran Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage.Design, Synthesis, and Biological and Structural Evaluations of Novel HIV-1 Protease Inhibitors To Combat Drug Resistance Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus Structure of a G48H mutant of HIV-1 protease explains how glycine-48 replacements produce mutants resistant to inhibitor drugs Molecular recognition of cyclic urea HIV-1 protease inhibitors In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632 In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor.Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure.Characterization of human immunodeficiency virus type 1 resistant to modified cyclodextrin sulphate (mCDS71) in vitro Anti-human immunodeficiency virus (HIV) activities of halogenated gomisin J derivatives, new nonnucleoside inhibitors of HIV type 1 reverse transcriptase

P2860

Q24530002-0CA376C5-2165-4FDE-849D-3472181F1D87 Q24534187-5F1A73D1-36AF-4EEE-8A43-476A4904857C Q24554340-587F2BE0-FDEF-4383-ACED-F4891F68F567 Q24555227-6F6E3D7D-479B-4CA3-97C9-76699ADF8692 Q24642446-F1979B78-60A2-455D-8630-56788E8CA52D Q24645221-0283983A-6C1D-42F8-A0DB-F1ED59171402 Q24656978-24C89E1D-6789-41A3-BF9F-760AD5ED3C24 Q24801797-FD704C30-9E49-4BD6-A638-2ADA1C9485E8 Q27469337-D739313B-8328-4734-8E19-B8C3ECB57BBB Q27480780-52DA8196-6AA5-4590-ACFB-E61BD2B90812 Q27619254-E7715EA8-CB6A-4972-9A45-9DBBD3C6A433 Q27620967-DD6F25F0-8F88-4166-AA50-0FA0B9D9BA51 Q27621075-FE57C0DD-0D85-4420-AB5A-B60E161E47D4 Q27637329-23A26FEE-6085-4C50-B77D-5C945A08E5C0 Q27639159-7CBF9333-7006-499D-83B4-E3568478058C Q27640250-024E02F7-B3B5-4827-8F62-69FABA8EA42B Q27647177-AD17D179-BA3E-40D9-8C78-3E1968AFB17F Q27647665-4ED898F9-E446-4772-B9F4-A793C4A8EDC8 Q27650299-1B6AD367-62E2-4B99-99AE-F30058175FB3 Q27650325-4AA74760-B49D-458D-B149-41ADAF944FC1 Q27660267-8023357D-424D-4F06-B5BD-6D55058412EC Q27663981-0DC92962-2623-48C4-8A80-F434A3A7AE7A Q27666265-99134704-D421-45A8-A68A-0D9491E7A8B7 Q27666929-1D9A0E62-42C0-4793-A7EE-98E0C69E5F12 Q27676079-569E43BF-69E7-455D-ABE2-149AD1934E79 Q27677405-B5CF4E11-0A71-4E34-B290-8092E3D6FEE9 Q27680666-9F160580-0ED6-4C01-891F-60B21A896243 Q27681219-AC0EC118-EAF0-4C76-B74D-0244C59C4B42 Q27729877-B0F281DF-EFA3-4079-A46A-719BD4F280EB Q27748828-56FA2BB4-DE69-492D-ACE9-30F41D14085D Q27757042-BAC72D34-E88E-4C8D-A159-9F78E053D8FF Q28344355-8C4CA28C-9F09-49C2-AA35-F4A5CA3C53DC Q28344457-98EFCEFF-2C49-4EFF-A1A3-D4EFACEC09E1 Q28344594-E554D288-2BDD-4905-A2C1-153766F7D7A6 Q28367941-ECD88F34-4FCB-46F5-8D3E-CC72F433AB12 Q28368369-B2D88628-2E3E-43F0-95BD-E7AD239E72AB Q28369030-F253637A-FDCF-4749-A1A9-CDD2B7C32AD7 Q28369495-242E3447-44DC-4E9F-917B-6A67DB6B2655 Q28371764-BE1E6F33-10A5-44EC-814C-9B949162F3B5 Q28378745-4245016B-9AA6-4177-BABF-73E7F6D9FBE2

P2860

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

http://www.wikidata.org/entity/Q29620622

description

1995 nî lūn-bûn

@nan

1995 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

1995 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

1995年の論文

@ja

1995年論文

@yue

1995年論文

@zh-hant

1995年論文

@zh-hk

1995年論文

@zh-mo

1995年論文

@zh-tw

1995年论文

@wuu

name

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

@ast

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

@en

type

label

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

@ast

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

@en

prefLabel

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

@ast

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

@en

P1433

Q29620622-FC6ECB83-9A5E-41E7-B027-C6CD973503EF

P1476

Q29620622-AF066117-8779-4BAB-AC20-D336E5F91FEC

P2093

Q29620622-09FD7280-0134-43AB-9620-D542CBBC09EA

Q29620622-20B58FAA-D66B-492D-BCF6-03CD95F5360F

Q29620622-42752AEB-3EB9-4662-A99B-86BDA0F2E306

Q29620622-4CDC643D-98FC-420F-B4EB-ACDD2D5A80F3

Q29620622-83681068-1A6A-43B2-B23F-E87E438B1C4F

Q29620622-AE5237B9-1ADD-4815-A411-7D5B54AAE413

Q29620622-E1A5BB5E-FBF0-4023-BD62-A47B534CF6BE

Q29620622-EB5974D1-BD73-4200-A964-EAFBF2A12C12

Q29620622-EBF89A22-7621-494F-87F6-C4C3832DC092

Q29620622-F8BDFEE0-F1C5-4745-93DD-9951CA24F92C

P2888

Q29620622-E1DFE1AC-12A4-4359-8169-B451620556ED

P304

Q29620622-58A5B2E8-6DF6-42BA-9578-7A977A57C6C6

P31

Q29620622-F4FC8007-9AE4-418E-96B3-096053487428

P356

Q29620622-A8F7F5BD-497B-40AB-919B-4A9E972616C7

P407

Q29620622-B9BFBB95-125B-4EB8-BC0C-0337189328B2

P433

Q29620622-69F779D9-6576-4878-884B-58849EC4B67A

P478

Q29620622-06C972EA-1077-420A-AC47-9635962B95CC

P577

Q29620622-23C3944B-6E7A-4A33-B099-2387A5D21227

P6179

Q29620622-5E9FCD98-1D03-425B-A817-5360E9EDC636

P698

Q29620622-491111E4-943D-4ADA-9D8A-713F91392593

P356

P1433

P1476

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

@en

P2093

Blahy OM

http://www.w3.org/2001/XMLSchema#string

Condra JH

http://www.w3.org/2001/XMLSchema#string

Gabryelski LJ

http://www.w3.org/2001/XMLSchema#string

Graham DJ

http://www.w3.org/2001/XMLSchema#string

Quintero JC

http://www.w3.org/2001/XMLSchema#string

Rhodes A

http://www.w3.org/2001/XMLSchema#string

Robbins HL

http://www.w3.org/2001/XMLSchema#string

Roth E

http://www.w3.org/2001/XMLSchema#string

Schleif WA

http://www.w3.org/2001/XMLSchema#string

Shivaprakash M

http://www.w3.org/2001/XMLSchema#string

P2888

P304

569-71

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/374569A0

http://www.w3.org/2001/XMLSchema#string

P407

P433

6522

http://www.w3.org/2001/XMLSchema#string

P478

374

http://www.w3.org/2001/XMLSchema#string

P577

1995-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1012077404

http://www.w3.org/2001/XMLSchema#string

P698

7700387

http://www.w3.org/2001/XMLSchema#string